Conditions

The U.S. Food and Drug Administration has approved the oral therapy Lynparza (olaparib) for treating men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA or ATM. Approval is specific for men who failed prior treatment with Xtandi (enzalutamid) or Zytiga (abiraterone acetate), two hormone therapies. The decision was based on findings…

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations who have previously received an androgen receptor inhibitor and taxane-based chemotherapy. The agency’s decision was made under an accelerated approval process after previously granting the therapy breakthrough therapy designation…

A combination of ONCOS-102 plus standard chemotherapy continues to extend the time without disease progression and appears to induce immune system activity in people with malignant pleural mesothelioma unable to undergo surgery, updated results from a Phase 2 clinical trial show. Developed by Targovax, ONCOS-102 is a genetically modified adenovirus designed to infect cancer cells…

A new Phase 2 clinical trial in Australia will assess whether exercise can improve the quality of life and physical function of women with recurring ovarian cancer who are on chemotherapy. Researchers at Griffith University recently were awarded a AU$884,172 grant (about $581,000) from the Medical Research Future Fund for this project. They will collaborate with teams at…

For breast cancer care during the COVID-19 pandemic, a panel of experts has recommended that patients be divided into one of three categories based on the severity of their condition and the potential effectiveness of treatments. Top priority are patients who require urgent care immediately because of life-threatening conditions, while the second group includes those…

Only a couple of weeks after Rubraca (rucaparib) was approved for the treatment of prostate cancer, the National Comprehensive Cancer Network (NCCN) has updated its guidelines recommending this PARP inhibitor as an option for select prostate cancer patients in the U.S. According to Clovis Oncology, which makes Rubraca, the NCCN recommends Rubraca as a “treatment option…

Surface Oncology has entered a collaboration with Merck to investigate a combination of SRF617 and Keytruda (pembrolizumab) in patients with solid tumors, with a particular focus on individuals with gastric cancer and those who failed to respond to immune checkpoint inhibitors. This combination will be investigated as part of the first-in-human Phase 1/1b clinical trial…

Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, as a faster and easier alternative to treat people with multiple myeloma. The new formulation, combining daratumumab and hyaluronidase, is given to…

Women who breastfeed are at a significantly lower risk of developing ovarian cancer overall and some of its subtypes, including the deadliest — high-grade serous tumors, a large data study reported. This finding was particular to white women — because not enough black and Asian women could be included in the analysis — strengthened with longer…

Androgen deprivation therapy (ADT), a form of hormone therapy commonly used to treat prostate cancer, appears to confer protection against the virus that causes COVID-19, lowering the rate of infections and their severity, a new study suggests. The study, “Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study,” was published…